Abstract:Objective: To describe the clinical, chest imaging, pathological manifestations and therapeutic experience of human infection with A/H7N9 virus. Methods: The features of 15 laboratory-confirmed cases of human infection with A/H7N9 virus in Taizhou, Jiangsu Province were retrospectively analyzed. Results: The 15 patients with confirmed viral pneumonia included 12 males and 3 females, with a median age of 61 years(ranging from 33 to 81 years). Twelve patients had a history of exposure to the poultry trading places, or direct contact with ill/dead avian, while 3 patients denied exposure or contact. The most common initial symptoms were fever, coughing, and respiratory distress. The illness progressed rapidly to acute respiratory distress syndrome (ARDS). Lab tests showed normal (8 cases) or decreased (7 cases)white blood cell count , decreased (13 cases) lymphocyte count and proportion , increased creatine kinase (CK, 12 cases) and lactate dehydrogenase (LDH, 15 cases), and respiratory failure (13 cases). Chest radiographic examination showed that the most common features were inflammatory infiltration in the lung, with partial consolidation. The average time of the diagnosis with influenza viral nucleic acid and onset of an oral anti-influenza drug were 7.1 days and 6.5 days. All patients were treated by antiviral drugs (oral oseltamivir 150 mg q12 h and/or intravenous paramivir 600 mg qd), with mechanical ventilation in 9 cases, glucocorticoid therapy in 5 cases (intravenous methylprednisolone in 3 and dexamethasone in 2 patients), extracorporeal membrane oxygenation (ECMO) therapy in 2 cases, continuous renal replacement therapy (CRRT) in 6 cases, and artificial liver therapy in 1 case. The pulmonary pathology was observed from post-mortem biopsy for 2 fatal cases. Patient 1 had diffuse alveolar damage with inflammatory exudation, hyaline membrane formation, and cellular infiltration. Patient 2 had widened alveolar septum, lymphocyte and monocyte cell infiltration in the alveolar septa, and interstitial fibrous proliferation. Nine patients were discharged, and 6 died. Conclusions: Patients with influenza A/H7N9 virus mostly presented with fever, cough, and were prone to progression to viral pneumonia. Once acute respiratory distress and important organ dysfunction occurred, the fatality rate was higher. Early diagnosis and rational treatment were critical for better outcomes.

Evaluation of Plasma Exchange and Continuous Veno-Venous Hemofiltration for the Treatment of Severe Avian Influenza A (H7N9): a Cohort Study.

Evaluation of Plasma Exchange and Continuous Veno‐Venous Hemofiltration for the Treatment of Severe Avian Influenza <scp>A</scp> (<scp>H7N9</scp>): A Cohort Study

Laboratory findings in patients with avian-origin influenza A (H7N9) virus infections.

Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma.

The Serum Profile of Hypercytokinemia Factors Identified in H7n9-Infected Patients Can Predict Fatal Outcomes

Immune derangement occurs in patients with H7N9 avian influenza

Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus.

Severe Infection with Avian Influenza A Virus is Associated with Delayed Immune Recovery in Survivors

Analysis of the Clinical Characteristics and Treatment of Two Patients with Avian Influenza Virus (H7N9).

A New Perspective on C-Reactive Protein in H7n9 Infections

Analysis of 15 Cases of Avian Influenza Virus （H7N9） Infection

Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor.

Recovered and Dead Outcome Patients Caused by Influenza A (H7N9) Virus Infection Show Different Pro-Inflammatory Cytokine Dynamics During Disease Progress and Its Application in Real-Time Prognosis

Novel Pathogenic Characteristics of Highly Pathogenic Avian Influenza Virus H7N9: Viraemia and Extrapulmonary Infection

[Clinical Research of Plasma Exchange with Continuous Veno-Venous Hemofiltration in Treating Mid- and Late-Stage Chronic Severe Viral Hepatitis B Patients].

The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.

Prognosis and efficacy of integrative treatment for novel H7N9 avian influenza virus infection in human

Clinical findings in 111 cases of influenza A (H7N9) virus infection.

Angiotensin II Plasma Levels Are Linked to Disease Severity and Predict Fatal Outcomes in H7N9-infected Patients.

Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection

Long-term Clinical Prognosis of Human Infections with Avian Influenza A(H7N9) Viruses in China after Hospitalization